特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 证券代码：300165 证券简称：天瑞仪器 公告编号：2024-025 江苏天瑞仪器股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间： （1）现场会议时间：2024 年 5 月 17 日（星期五）下午 15:00 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 17 日 9:15-9:25，9:30-11:30 和 13:00-15:00； ②通过深圳证券交易所互联网投票系统进行网络投票的具体时间为：2024 年 5 月 17 日 9:15 至 15:00 期间的任意时间。 2、现场会议召开地点：昆山市玉山镇中华园西路 1888 号天瑞大厦八楼会议 室。 3、会议召开方式：本次股东大会采取网络投票和现场表决相结合的方式召 开。 4、会议召集人：公司董事会 5、会议主持人：董事长刘召贵先生 6、会议召 ...

上海市广发律师事务所 关于江苏天瑞仪器股份有限公司 2023 年年度股东大会的法律意见书 江苏天瑞仪器股份有限公司（以下简称"公司"）2023 年年度股东大会于 2024 年 5 月 17 日在江苏省昆山市中华园西路 1888 号天瑞大厦会议室召开。上 海市广发律师事务所经公司聘请，委派施敏律师、李伟一律师出席现场会议，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东大 会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律法规、其他 规范性文件以及《江苏天瑞仪器股份有限公司章程》（以下简称"《公司章程》"） 的规定，就本次股东大会的召集和召开程序、召集人及出席会议人员的资格、会 议议案、表决方式和表决程序、表决结果和会议决议等出具本法律意见书。 为出具本法律意见书，本所律师对本次股东大会所涉及的有关事项进行了审 查，查阅了相关会议文件，并对有关问题进行了必要的核查和验证。 公司已向本所保证和承诺，公司向本所律师所提供的文件和所作的陈述和说 明是完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一 切足以影响本法律意见书的事实和文件均已向本所披露，而无任何隐瞒 ...

深 圳 证 券 交 易 所 江苏天瑞仪器股份有限公司董事会 ： 我部在对你公司 2023 年度报告（以下简称年报）进行 事后审查的过程中，关注到以下情况： 1.年报显示，你公司报告期实现营业收入 101,721.24 万元，扣非后归属于上市公司股东的净利润（以下简称扣非 后净利润）-11,809.16 万元，分别同比下滑 27.55%、26.02%； 扣非后净利润已连续五年为负值，且亏损金额逐年增加。 请你公司： （1）结合行业环境、公司竞争力、同行业可比公司经营 情况等因素，说明公司扣非后净利润连续五年为负值、亏损 金额逐年增加的原因，在此基础上说明公司持续经营能力是 否存在重大不确定性，公司采取持续经营假设为基础编制年 报的依据及合理性； （2）说明在主营业务持续亏损的情况下，公司各类生产 1 关于对江苏天瑞仪器股份有限公司的 年报问询函 创业板年报问询函〔2024〕第 85 号 经营相关的固定资产、在建工程和无形资产是否存在重大减 值风险，相关资产减值准备计提情况及其合理性、充分性。 2.你公司于 2023 年度两次进行会计差错更正，主要涉 及 PPP 项目收入核算。在此基础上，你公司再次于 2024 ...

深 圳 证 券 交 易 所 关于对江苏天瑞仪器股份有限公司的 年修订）》第 7.1.4 条的规定。 我部提醒你公司：上市公司必须按照国家法律、法规， 本所《创业板股票上市规则》及相关规定，认真和及时地履 行信息披露义务。上市公司的董事会全体成员必须保证信息 披露内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏，并就其保证承担个别和连带的责任。 特此函告。 监管函 创业板监管函〔2024〕第 74 号 江苏天瑞仪器股份有限公司董事会： 你公司前期披露的公告显示，2017 年 4 月、2018 年 4 月，经董事会审议通过，公司分别将 5,000 万元、7,000 万 元超募资金用于永久补充流动资金。自 2017 年 12 月起，公 司存在为员工购房购车提供借款情形，构成对外提供财务资 助，前述行为违反了超募资金永久补充流动资金后的十二个 月内不得对外提供财务资助的规定。对于公司使用超募资金 永久补充流动资金十二个月后持续存在的财务资助，公司未 及时履行董事会审议程序及信息披露义务，直至 2023 年 11 月 10 日才补充履行董事会审议程序及信息披露义务。 你公司的上述行为违反了本所《创业板股票上市 ...

Financial Performance - The net profit attributable to shareholders of the listed company for 2023 was -114.43 million yuan, a year-on-year decrease of 30.23%[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -118.09 million yuan, a year-on-year decrease of 26.02%[4]. - The decline in performance was primarily due to significant goodwill impairment recognized by subsidiaries[4]. - The company's operating revenue for 2023 was ¥1,017,212,385.17, a decrease of 27.55% compared to ¥1,403,971,007.01 in 2022[26]. - The net profit attributable to shareholders for 2023 was -¥114,432,116.75, representing a decline of 30.23% from -¥87,867,219.23 in 2022[26]. - The basic earnings per share for 2023 was -¥0.23, a decline of 27.78% from -¥0.18 in 2022[26]. - The company has faced uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profit figures over the last three accounting years[28]. - The company reported a total revenue after deducting unrelated business income of ¥984,745,364.58 for 2023, down from ¥1,376,801,432.21 in 2022[28]. Cash Flow and Assets - The net cash flow from operating activities improved by 50.88%, reaching -¥202,352,290.56 in 2023 compared to -¥411,982,505.66 in 2022[26]. - The total assets at the end of 2023 were ¥3,756,441,828.51, a decrease of 3.01% from ¥3,872,890,109.03 at the end of 2022[27]. - The net assets attributable to shareholders decreased by 8.89% to ¥1,384,727,884.10 in 2023 from ¥1,519,874,655.45 in 2022[27]. - The company has a significant amount of accounts receivable, leading to pressure on cash flow and capital turnover[11]. - The company's cash and cash equivalents decreased by 41.69% to ¥239,169,479.20, mainly due to reduced PPP project loans[142]. Research and Development - The company plans to increase R&D investment to enhance technological innovation and improve competitive capabilities[4]. - Research and development expenses increased by 30%, totaling 150 million yuan, reflecting the company's commitment to innovation[81]. - The company is focusing on developing new technologies in water quality analysis, aiming to introduce at least three new products in this category by the end of 2024[82]. - The company has made significant investments in R&D, maintaining its leadership position in the domestic analysis instrument industry[79]. - The company has developed multiple new products, including portable dissolved oxygen meters and air quality detection gas chromatographs, with patents granted[99]. Market and Competition - The company will continue to face risks from intensified market competition and potential declines in gross margin[6]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market presence[83]. - The company is positioned to benefit from the accelerated domestic substitution process in the analysis instrument market, enhancing its competitive edge[78]. - The environmental governance industry is experiencing rapid growth, driven by increased government investment and regulatory support[41]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share within the next two years[81]. Product Development and Innovation - The company has developed a comprehensive product line in the analysis and detection sector, focusing on spectrometers, chromatographs, and mass spectrometers, which are widely used across various industries including electronics, petrochemicals, and food safety[60]. - The company has successfully developed multiple models of semiconductor testing instruments, including energy dispersive X-ray fluorescence spectrometers and wavelength dispersive X-ray fluorescence spectrometers, with ongoing R&D for high-power wavelength dispersive X-ray wafer analyzers aimed at domestic market needs[68]. - The company has introduced a new software suite for its X-ray fluorescence spectrometers, enhancing user experience and functionality[102]. - The company has launched a new Android-based industrial control computer that is compact, low-power, and highly expandable, aligning with industry trends[113]. - The company has developed advanced fluorescent labeling technology, which shows high sensitivity and stability for end product labeling[85]. Environmental and Regulatory Compliance - The company is exploring business in ecological protection and environmental governance through PPP projects, which carry operational risks due to large investment amounts and long cooperation periods[8]. - The implementation of new regulations in 2023 strengthens the quality safety responsibilities of medical device manufacturers, enhancing management oversight[56]. - The company has established partnerships for environmental technology, indicating a collaborative approach to market expansion[90]. - The company aims to achieve carbon neutrality in its operations by 2025, aligning with global sustainability trends[96]. - The company has focused on R&D for automatic monitoring systems, which aligns with current trends in automation and efficiency in environmental monitoring[90]. Subsidiaries and Acquisitions - The company has successfully completed several acquisitions using over-raised funds, including 100% equity of Suzhou Tianrui Environmental Technology Co., Ltd. for 81.78 million yuan and Shanghai Beixi Biotechnology Co., Ltd. for 360 million yuan[155]. - The company is currently in the process of liquidating Shenzhen Tianrui, which will no longer be included in the consolidated financial statements as of June 2023[129]. - The subsidiary Bexi reported a net loss of 26.6837 million CNY, indicating challenges in the medical device sector[161]. - The company has initiated a strategic acquisition of a local environmental technology firm, which is expected to enhance its service capabilities and market reach[165]. - The company has completed clinical trials for the influenza virus antigen detection kit and is in the process of registering it as a medical device[134].

江苏天瑞仪器股份有限公司 2023 年度 公证天业会计师事务所（特殊普通合伙） 审计报告 Gongzheng Tianye Certified Public Accountants, SGP | 中国．江苏．无锡 | Wuxi．Jiangsu．China | | --- | --- | | 总机：86（510）68798988 | Tel：86（510）68798988 | | 传真：86（510）68567788 | Fax：86（510）68567788 | | 电子信箱：mail@gztycpa.cn | E-mail：mail@gztycpa.cn | 审计报告 苏公 W[2024]A636 号 江苏天瑞仪器股份有限公司全体股东： 一、审计意见 我们审计了江苏天瑞仪器股份有限公司（以下简称天瑞仪器）财务报表，包 括2023年12月31日的合并及母公司资产负债表，2023年度的合并及母公司利润表、 合并及母公司现金流量表、合并及母公司所有者权益变动表以及相关财务报表附 注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了天瑞仪器2023年12月31日的合并及母公司财务状况 ...

江苏天瑞仪器股份有限公司 前期会计差错更正专项说明的鉴证报告 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 中国．江苏．无锡 Wuxi．Jiangsu．China 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 关于江苏天瑞仪器股份有限公司 前期会计差错更正专项说明的鉴证报告 苏公W[2024]E1251号 江苏天瑞仪器股份有限公司全体股东： 我们的责任是在实施鉴证工作的基础上对专项说明发表鉴证意见。我们按 照《中国注册会计师其他鉴证业务准则第 3101 号——历史财务信息审计或审阅 以外的鉴证业务》的规定执行了鉴证业务。该准则要求我们遵守职业道德规范， 计划和实施鉴证工作，以对专项说明是否存在重大错报获取合理保证。在鉴证 过程中，我们实施了包括抽查会计记录、重新计算等我们认为必要的工作程序。 我们相信，我们的鉴证工作为发表 ...

江苏天瑞仪器股份有限公司 资金占用情况的专项说明 2023 年度 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP 总机：86（510）68798988 Tel：86（510）68798988 传真：86（510）68567788 Fax：86（510）68567788 电子信箱：mail@gztycpa.cn E-mail：mail@gztycpa.cn 中国．江苏．无锡 Wuxi．Jiangsu．China 关于江苏天瑞仪器股份有限公司 非经营性资金占用及其他关联资金往来情况的专项 说明 苏公W[2024] E1252号 我们接受委托，按照中国注册会计师审计准则审计了江苏天瑞仪器股份有 限公司（以下简称天瑞仪器）财务报表，包括 2023 年 12 月 31 日的合并及母公 司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务报表附注，并于 2024 年 4 月 24 日出具了苏公 W[2024] A636 号无保留意见审计报告。 根据中国证券监督管理委员 ...

江苏天瑞仪器股份有限公司 内部控制鉴证报告 2023 年度 公证天业会计师事务所（特殊普通合伙） Gongzheng Tianye Certified Public Accountants, SGP | 中国．江苏．无锡 | Wuxi．Jiangsu．China | | --- | --- | | 总机：86（510）68798988 | Tel：86（510）68798988 | | 传真：86（510）68567788 | Fax：86（510）68567788 | | 电子信箱：mail@gztycpa.cn | E-mail：mail@gztycpa.cn | 内部控制鉴证报告 苏公W[2024]E1255号 江苏天瑞仪器股份有限公司全体股东： 我们接受委托，对江苏天瑞仪器股份有限公司（以下简称天瑞仪器）董事会 《内部控制自我评价报告》涉及的2023年12月31日财务报告内部控制有效性的认 定进行了鉴证。 一、董事会对内部控制的责任 按照《企业内部控制基本规范》的规定，建立健全和有效实施内部控制， 并评价其有效性是天瑞仪器董事会的责任。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对财务报 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥136,466,186.01, a decrease of 29.17% compared to ¥192,666,024.74 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥8,478,825.34, representing a decline of 195.47% from a profit of ¥8,881,056.49 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.02, a decrease of 200.00% from ¥0.02 in the same period last year[5] - The weighted average return on equity was -0.61%, down from 0.58% in the previous year[5] - The net profit for Q1 2024 was -8,357,695.27 CNY, compared to a net profit of 7,566,940.51 CNY in Q1 2023, indicating a significant decline[26] - Operating profit for Q1 2024 was -8,021,030.80 CNY, down from 10,828,033.32 CNY in the same period last year[26] - The total comprehensive income for Q1 2024 was -8,357,695.27 CNY, compared to 7,566,940.51 CNY in Q1 2023[27] - The company incurred financial expenses of -15,624,159.56 CNY in Q1 2024, compared to -12,191,237.82 CNY in Q1 2023, indicating an increase in financial costs[26] Cash Flow - The net cash flow from operating activities improved to -¥17,045,952.67, a 78.81% increase compared to -¥80,450,899.47 in the same period last year[5] - The net cash flow from investing activities was -¥340,250.00, a 95.09% improvement from -¥6,933,870.00 in the same period last year[13] - The net cash flow from financing activities decreased by 85.49% to ¥1,569,700.00, primarily due to reduced external borrowings[13] - Cash flow from operating activities was -17,045,952.67 CNY in Q1 2024, an improvement from -80,450,899.47 CNY in Q1 2023[29] - The investment activities generated a net cash flow of -3,402,497.57 CNY in Q1 2024, compared to -69,338,720.37 CNY in Q1 2023, showing a reduction in cash outflow[31] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥3,773,839,966.08, reflecting a slight increase of 0.46% from ¥3,756,441,828.51 at the end of the previous year[5] - Total liabilities as of Q1 2024 were CNY 2,348,412,044.29, compared to CNY 2,322,947,416.40 at the beginning of the period, reflecting a slight increase of 1.1%[22] - Non-current assets totaled CNY 482,921,332.66, up from CNY 472,083,932.13, indicating a growth of 2.0%[21] - The total assets at the end of Q1 2024 were CNY 3,773,839,966.08, compared to CNY 3,756,441,828.51 at the beginning of the period, showing a slight increase of 0.5%[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,775[15] - Liu Zhaogui holds 16.13% of shares, totaling 79,914,203 shares, with 59,935,652 shares under lock-up[15] - Guangzhou Lidu Virtual Reality Technology Partnership holds 5.01% of shares, totaling 24,825,137 shares[15] - The company has a total of 74,983,040 shares under lock-up due to executive restrictions[18] - The company reported a total of 21,000,000 shares held by Shanghai Muxin Private Fund Management Co., which is part of the top shareholders[16] - The top ten shareholders include individuals and private funds, with varying percentages of ownership[16] - Liu Zhaogui and Shanghai Muxin Private Fund Management Co. are identified as acting in concert[16] - The company has not reported any changes in the number of shares due to lending or borrowing activities in the current period[17] - The company has a total of 74,983,040 shares under lock-up, with no shares released during the reporting period[18] Revenue and Costs - Total operating revenue for Q1 2024 was CNY 136,466,186.01, a decrease of 29.2% compared to CNY 192,666,024.74 in the same period last year[25] - Total operating costs for Q1 2024 were CNY 146,220,580.29, down from CNY 183,913,517.90, reflecting a reduction of 20.5%[25] - The total revenue from operating activities was 212,661,017.02 CNY in Q1 2024, compared to 270,522,513.80 CNY in Q1 2023, representing a decrease of about 21.4%[29] Other Financial Metrics - The intangible assets increased by 115.78% to ¥38,960,800.00 due to the trial operation of a PPP project[10] - Research and development expenses increased to 21,040,990.78 CNY in Q1 2024, up from 16,697,507.47 CNY in Q1 2023, reflecting a growth of approximately 26.0%[26] - Cash and cash equivalents at the end of Q1 2024 were CNY 234,417,835.51, a slight decrease from CNY 239,169,479.20 at the beginning of the period[20] - Accounts receivable decreased to CNY 350,561,663.80 from CNY 377,904,493.54, indicating a reduction of 7.2%[20] - Inventory increased to CNY 565,397,807.66 from CNY 541,417,298.39, representing a growth of 4.4%[20] - Contract assets rose to CNY 2,016,338,193.76 from CNY 1,998,701,680.97, an increase of 0.9%[20] - The company reported a decrease in undistributed profits to CNY 33,252,034.25 from CNY 41,730,859.59, a decline of 20.4%[23] - The financial statements for the first quarter of 2024 are prepared and available for review[19]